CAMBRIDGE, MA – On October 14, 2017, the ALS Therapy Development Institute (ALS TDI) will host the 7th annual White Coat Affair gala at the Sheraton Boston Hotel. The gala is a special night honoring those living with ALS, and those who have passed from the disease. The evening features a cocktail reception, dinner, guest speakers, live music and a late night after-party. Special guest speakers include two young women living with ALS, Angelina Fanous of HBO’s Vice and Beth Hebron of “The Styled Mannequin.”

"The White Coat Affair isn’t like just any other gala" says Carol Hamilton, Director of Development at ALS TDI, "Sharing an evening so many people who are passionate about ending ALS, many of whom are living with the disease or have lost someone, is amazing. The event is like a huge family reunion.  Nothing makes me happier or prouder than to see the dance floor filled with folks whose lives are dedicated to changing the future of ALS.”

Since 2011, the White Coat Affair has raised over $2 million for ALS drug discovery and development, with a goal of raising $500,000 in 2017. All proceeds from the White Coat Affair gala benefit the ALS Therapy Development Institute, a non-profit biotech led by people with ALS and drug development experts and the world’s foremost drug discovery center focused solely on ALS.

“The White Coat Affair gala is an annual gathering for the ALS community and a time to catch up on what’s happened in research throughout the year. 2017 held huge hope for those living with ALS. We saw the first drug for ALS approved by the FDA in 20 years, plus many other potential therapies are currently in the pipeline.” says Steve Perrin CEO and CSO of the ALS Therapy Development Institute. I look forward to celebrating all that has been accomplished at this year’s event while not losing sight of the work that still needs to be done.”

Tickets for the event are $250 or $150 for young professionals. Tickets to the after party are available for $50. People living with ALS and their care givers are guests of ALS TDI and attend for free. For more information, see last year’s photos, or purchase tickets for this year’s White Coat Affair, please visit www.whitecoataffair.com or email events@als.net.  

 

About the ALS Therapy Development Institute
The ALS Therapy Development Institute (ALS TDI) and its scientists actively discover and develop treatments for ALS. It is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by people with ALS and drug development experts, ALS TDI understands the urgent need to slow and stop this disease.

Based in Cambridge, MA, ALS TDI has over 30 full-time, industry trained, drug development experts on staff. ALS TDI is internationally recognized as a leader in optimizing preclinical models of neurodegeneration for clinical translation, and partners with pharmaceutical companies and biotechs around the world. Rated a CharityNavigator.com four-star charity, ALS TDI spends 87% of each dollar raised on research to find an effective treatment and cure. Visit www.als.net.

 

Media contact:

Colette O’Neill | ALS Therapy Development Institute | Senior Director of Marketing, PR + Communications | coneill@als.net